BioPharmSignal logoBioPharmSignal

Biotech News

MoonLake Immunotherapeutics reports on week 16 results of the VELA Phase 3 hidradenitis suppurativa program with the Nanobody® sonelokimab

MoonLake Immunotherapeutics (MLTX)MoonLake ImmunotherapeuticsClinical readout

VELA-1 and VELA-2 are two identical trials to evaluate the efficacy and safety of sonelokimab in adult participants with moderate to severe hidradenitis suppurativa (HS) and the first Phase 3 program using the higher clinical response level of HS Clinical Response (HiSCR) 75 as primary endpoint at

Related news

MLTXMoonLake Immunotherapeutics2026-06-21 21:00 EST

MoonLake Announces Week 52 Results of Sonelokimab from its Phase 3 VELA Program in Hidradenitis Suppurativa and Confirms Investor Day on June 22, 2026

MLTXMoonLake Immunotherapeutics2026-08-10 11:00 EST

MoonLake Announces Positive Topline Results from the Phase 3 IZAR-1 Trial of Sonelokimab in Psoriatic Arthritis Demonstrating Significant Improvements Across all Clinical Endpoints, and Reports Second Quarter 2026 Financial Results

ZURAZura Bio2026-06-29 11:30 EST

Zura Bio Exceeds Enrollment Target in Both Hidradenitis Suppurativa (HS) & Systemic Sclerosis (SSc) Phase 2 Studies and Expands Tibulizumab Program

ENTAEnanta Pharmaceuticals2026-06-18 11:00 EST

Enanta Pharmaceuticals Announces Advancement of its Zelicapavir Clinical Development Program for the Treatment of Respiratory Syncytial Virus (RSV)

CLDXCelldex Therapeutics2026-06-14 09:15 EST

Celldex Presents Positive First-in-Human Results from Phase 1 Study of Novel Bispecific CDX-622 at the European Academy of Allergy and Clinical Immunology Annual Meeting

APGEApogee Therapeutics2026-05-27 10:30 EST

Apogee Therapeutics Announces Positive 16-Week Part B Induction Dose Optimization Results from Phase 2 APEX Trial of Zumilokibart in Moderate-to-Severe Atopic Dermatitis

ARGXArgenx2026-08-17 05:00 EST

argenx Announces Positive Topline Results from Phase 3 ALKIVIA Trial of Efgartigimod in Autoimmune Myositis

NRIXNurix Therapeutics2026-08-04 11:00 EST

Nurix Announces $10 Million Milestone Payment Associated with Initiation of a Phase 1 Clinical Trial of a STAT6 Degrader

KYMRKymera2026-06-12 11:00 EST

Kymera Therapeutics Presents Phase 1 Data in Healthy Japanese Adults for KT-621, a First-in-Class Oral STAT6 Degrader, at the Japanese Dermatological Association Annual Meeting

CLDXCelldex Therapeutics2026-07-21 20:01 EST

Celldex Reports Results from Phase 2 Study of Barzolvolimab in Prurigo Nodularis

View all latest news

MoonLake Immunotherapeutics

Nanobody-Based Immunology MoonLake Immunotherapeutics develops therapies for inflammatory diseases using Nanobodies, compact antibody-derived proteins designed for tissue penetration, molecular stability and multivalent target binding. Sonelokimab Sonelokimab is a trivalent Nanobody that binds IL-17A and IL-17F while also interacting...

Recent company news

MLTXMoonLake Immunotherapeutics2026-08-10 11:00 EST

MoonLake Announces Positive Topline Results from the Phase 3 IZAR-1 Trial of Sonelokimab in Psoriatic Arthritis Demonstrating Significant Improvements Across all Clinical Endpoints, and Reports Second Quarter 2026 Financial Results

MLTXMoonLake Immunotherapeutics2026-06-24 03:08 EST

MoonLake Immunotherapeutics Announces Pricing of Upsized $200 Million Public Offering

MLTXMoonLake Immunotherapeutics2026-06-22 20:01 EST

MoonLake Immunotherapeutics Announces Proposed Public Offering

MLTXMoonLake Immunotherapeutics2026-06-21 21:00 EST

MoonLake Announces Week 52 Results of Sonelokimab from its Phase 3 VELA Program in Hidradenitis Suppurativa and Confirms Investor Day on June 22, 2026

MLTXMoonLake Immunotherapeutics2026-05-10 13:00 EST

MoonLake Immunotherapeutics Announces Positive Outcome from its Final Pre-BLA Meeting with the U.S. FDA and Reports First Quarter 2026 Financial Results

Stock data

Close
15.76 USD
Market cap
1.32B USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States